Clene Inc. (Clene) reported a net loss of $7.986 million for the third quarter ended September 30, 2024, compared to a net loss of $2.418 million for the same period in 2023. The diluted net loss per share was $1.22 for the quarter, a significant increase from $0.38 in the previous year. The company's revenue from related parties for the quarter was $86,000, a decrease from $107,000 in the prior year. Clene also closed a registered direct offering on October 1, 2024, with gross proceeds of approximately $3.5 million before fees and expenses. In business development, Clene amended its License and Supply Agreements with 4Life, granting exclusive rights to purchase and sell certain dietary supplements. Clene provides Zinc Factor™ and Gold Factor™ supplements to 4Life. The company's future plans include continuing clinical trials for its lead drug candidate, CNM-Au8, in various central nervous system disorders, with a focus on ALS, MS, and PD. Clene is also evaluating the accounting for proceeds from the recent offerings and the classification of associated equity securities.

Clene Inc. (Clene) reported a net loss of $7.986 million for the third quarter ended September 30, 2024, compared to a net loss of $2.418 million for the same period in 2023. The diluted net loss per share was $1.22 for the quarter, a significant increase from $0.38 in the previous year. The company's revenue from related parties for the quarter was $86,000, a decrease from $107,000 in the prior year. Clene also closed a registered direct offering on October 1, 2024, with gross proceeds of approximately $3.5 million before fees and expenses. In business development, Clene amended its License and Supply Agreements with 4Life, granting exclusive rights to purchase and sell certain dietary supplements. Clene provides Zinc Factor™ and Gold Factor™ supplements to 4Life. The company's future plans include continuing clinical trials for its lead drug candidate, CNM-Au8, in various central nervous system disorders, with a focus on ALS, MS, and PD. Clene is also evaluating the accounting for proceeds from the recent offerings and the classification of associated equity securities.